<DOC>
	<DOC>NCT02111031</DOC>
	<brief_summary>The objective of the registry study is to demonstrate the clinical utility of the CELLSEARCH® CTC Test among the Medicare-Eligible metastatic Breast Cancer (mBC) patients in the United States. The objective of the present registry is to demonstrate the impact on patient management of the CELLSEARCH® CTC Test among the Medicare-eligible mBC patients. Hereto the hypothesis that the availability of CTC information provides clinicians important, timely information and impacts treatment decisions, will be tested. This study is IDE-exempt since CELLSEARCH® CTC Test is a legally marketed device in the US, and is being used in accordance with its labeling.</brief_summary>
	<brief_title>Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patient has documented (histologically/pathologically confirmed) mBC diagnosis Patient is at least 65 years of age at time of mBC diagnosis Patient is male or female Patient is being actively treated at the cancer center by a physician who uses or plans to use CTC testing on his mBC patients at lease every quarter. Patients breast cancer is secondary not primary</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CELLSEARCH</keyword>
	<keyword>CTC</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>Registry</keyword>
	<keyword>mBC</keyword>
</DOC>